2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-135094
    Palmitoyl glutamic acid 38079-66-2 ≥98.0%
    Palmitoyl glutamic acid (N-Palmitoyl-L-glutamic acid) is an acyl amino acid with neuroprotective effects. Palmitoyl glutamic acid is used as cosmetic material.
    Palmitoyl glutamic acid
  • HY-135572
    TLX agonist 1 958323-31-4 99.94%
    TLX agonist 1 (ccrp2) is an orphan nuclear receptor tailless (TLX, NR2E1) modulator (EC50=1μM; Kd= 650 nM). TLX agonist 1 potentiates TLX transcriptional repressive activity.
    TLX agonist 1
  • HY-135761
    Penconazole 66246-88-6 98.91%
    Penconazole is a typical triazole fungicide, and mainly applied on apples, grapes, and vegetables to control powdery mildew. Penconazole inhibits sterol biosynthesis in fungi. Penconazole decrease AChE activity in the cerebrum and cerebellum of rats.
    Penconazole
  • HY-135868
    Mito-apocynin (C2) 1254044-41-1 98.38%
    Mito-apocynin (C2), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP + cation. Mito-apocynin (C2) exhibits antineuroinflammatory effect.
    Mito-apocynin (C2)
  • HY-136281
    DuP 734 135135-87-4 98.82%
    DuP 734 is a sigma receptor antagonist. DuP 734 is a selective and potent sigma and 5-HT2 receptor ligand with weak affinity for D2 receptors. DuP 734 may have antipsychotic activity without the liability of motor side effects typical of neuroleptics.
    DuP 734
  • HY-136424
    GPI-1485 186268-78-0 99.88%
    GPI-1485 (GM1485), a nonimmunosuppressive immunophilin ligand, promotes neurofunctional improvement and neural regeneration following stroke.
    GPI-1485
  • HY-136661
    (-)-N6-Phenylisopropyl adenosine 38594-96-6 99.45%
    (-)-N6-phenylisopropyl adenosine (D-phenylisopropyladenosine) is a adenosine receptor agonist. (-)-N6-phenylisopropyl adenosine inhibits K+-evoked Ca2+ uptake with an IC50 value of 0.5 µM.
    (-)-N6-Phenylisopropyl adenosine
  • HY-136706
    Luciferase-IN-1 10205-56-8 99.59%
    Luciferase-IN-1 is a luciferase inhibitor.
    Luciferase-IN-1
  • HY-138119
    γ-Glutamylserine 5875-35-4 98.35%
    γ-Glutamylserine (γ-Glu-Ser) is a calcium receptor activator. γ-Glutamylserine can be used for Parkinson's disease research, as well as diabetes or obesity study.
    γ-Glutamylserine
  • HY-138233
    KUS121 1357164-52-3 ≥98.0%
    KUS121, a valosin-containing protein (VCP, p97) modulator with significant neuroprotective effects, attenuates ischemic retinal cell death via suppressing endoplasmic reticulum stress.
    KUS121
  • HY-138643
    Cl-NQTrp 185351-23-9 99.97%
    Cl-NQTrp signifcantly disrupts the preformed fbrillar aggregates of Tau-derived PHF6 (VQIVYK) peptide and full-length tau protein.
    Cl-NQTrp
  • HY-138903
    L-Homocysteic acid 14857-77-3 ≥98.0%
    L-Homocysteic acid (L-HCA) is an endogenous excitatory amino acid that acts as a NMDA receptor agonist (EC50: 14 μM). L-Homocysteic acid is neurotoxic, and can be used in the research of neurological disorders.
    L-Homocysteic acid
  • HY-139059
    ERD03 1377897-01-2 99.39%
    ERD03 is a potent disruptor of the EXOSC3-RNA interaction, with a Kd of 17±7 μM . ERD03 induces PCH1B-like phenotype in zebrafish embryo and can be used for neurological disorder disease research.
    ERD03
  • HY-139196
    ThioLox 1202193-89-2 99.74%
    ThioLox is a competitive 15-lipoxygenase-1 (15-LOX-1) inhibitor with a Ki of 3.30 μM. ThioLox shows anti-inflammatory and neuroprotective properties.
    ThioLox
  • HY-139451
    ELOVL6-IN-3 712346-06-0 99.19%
    ELOVL6-IN-1 is a potent, orally active and selective ELOVL6 inhibitor. ELOVL6-IN-1 dose-dependently inhibits mouse ELOVL6 activities, with an IC50 value of 0.350 μM. ELOVL6-IN-1 inhibits ELOVL6 in a noncompetitive manner for malonyl-CoA (Ki=994 nM) and palmitoyl-CoA.
    ELOVL6-IN-3
  • HY-141661
    Aβ/tau aggregation-IN-1 2252162-81-3 98.10%
    Aβ/tau aggregation-IN-1 is a potent Aβ1-42 β-sheets formation and tau aggregation inhibitor. The KD values of Aβ/tau aggregation-IN-1 with Aβ1-42 and tau are 160 μM and 337 μM, respectively. Aβ/tau aggregation-IN-1 can permeate the blood-brain barrier.
    Aβ/tau aggregation-IN-1
  • HY-141804
    ER176 1373887-29-6 99.77%
    ER176 is a next generation PET radioligand for imaging 18 kDa translocator protein (TSPO), a biomarker for neuroinflammation.
    ER176
  • HY-142042
    3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles 287196-91-2 99.84%
    3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles is an inhibitor for bone morphogenetic protein 2 (BMP2) with an IC50 of 2.2 μM. 3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles is inhibitor for mitogen-activated protein kinase 1 (MEK1). 3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles exhibits anti-inflammatory and neuroprotective activity in EAE mouse model.
    3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles
  • HY-143316
    NPR-C activator 1 2768328-61-4 99.30%
    NPR-C activator 1 (Compound 1) is a potent activator of natriuretic peptide receptor C (NPR-C). C-type natriuretic peptide (CNP) is involved in the regulation of vascular homeostasis. NPR-C activator 1 is identified as a potent agonist (EC50 ∼ 1 μM) with promising in vivo pharmacokinetic properties.
    NPR-C activator 1
  • HY-143333
    Nrf2 activator-3 2766570-23-2 98.26%
    Nrf2 activator-3 is a potent Nrf2 activator. Nrf2 activator-3 is used for cerebral ischemic injury research.
    Nrf2 activator-3
Cat. No. Product Name / Synonyms Application Reactivity